☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Approval
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
October 4, 2024
Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)
October 1, 2024
Establishment Labs Reports the US FDA’s Approval of Motiva Implants
September 27, 2024
BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia
September 27, 2024
IntraBio’s Aqneursa Receives the US FDA’s Approval for Treating Niemann-Pick Disease Type C
September 26, 2024
AstraZeneca’s Tagrisso Receives the US FDA’s Approval for Treating Unresectable, Stage III EGFR-Mutated Lung Cancer
September 26, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.